Development and Optimization of a Bladder Cancer Algorithm Using SEER-Medicare Claims Data.

IF 3.3 Q2 ONCOLOGY JCO Clinical Cancer Informatics Pub Date : 2024-09-01 DOI:10.1200/CCI.24.00073
John L Gore, Phoebe Wright, Vanessa Shih, Nancy N Chang, Sina Noshad, Gabriel G Rey, Steven Wang, Sujata Narayanan
{"title":"Development and Optimization of a Bladder Cancer Algorithm Using SEER-Medicare Claims Data.","authors":"John L Gore, Phoebe Wright, Vanessa Shih, Nancy N Chang, Sina Noshad, Gabriel G Rey, Steven Wang, Sujata Narayanan","doi":"10.1200/CCI.24.00073","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Categorizing patients with cancer by their disease stage can be an important tool when conducting administrative claims-based studies. As claims databases frequently do not capture this information, algorithms are increasingly used to define disease stage. To our knowledge, to date, no study has used an algorithm to categorize patients with bladder cancer (BC) by disease stage (non-muscle-invasive BC [NMIBC], muscle-invasive BC [MIBC], or locally advanced/metastatic urothelial carcinoma [la/mUC]) in a US-based health care claims database.</p><p><strong>Methods: </strong>A claims-based algorithm was developed to categorize patients by disease stage on the basis of the administrative claims portion of the SEER-Medicare linked data. The algorithm was validated against a reference SEER registry, and the algorithm's parameters were iteratively modified to improve its performance. Patients were included if they had an initial diagnosis of BC between January 2016 and December 2017 recorded in SEER registry data. Medicare claims data were available for these patients until December 31, 2019. The algorithm was evaluated by assessing percentage agreement, Cohen's kappa (κ), specificity, positive predictive value (PPV), and negative predictive value (NPV) against the SEER categorization.</p><p><strong>Results: </strong>A total of 15,484 patients with SEER-confirmed BC were included: 10,991 (71.0%) with NMIBC, 3,645 (23.5%) with MIBC, and 848 (5.5%) with la/mUC. After multiple rounds of algorithm optimization, the final algorithm had an agreement of 82.5% with SEER, with a κ of 0.58, a PPV of 87.0% for NMIBC, and 76.8% for MIBC and a high NPV for la/mUC of 98.0%.</p><p><strong>Conclusion: </strong>This claims-based algorithm could be a useful approach for researchers conducting claims-based studies categorizing patients with BC at diagnosis.</p>","PeriodicalId":51626,"journal":{"name":"JCO Clinical Cancer Informatics","volume":"8 ","pages":"e2400073"},"PeriodicalIF":3.3000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11421559/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JCO Clinical Cancer Informatics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1200/CCI.24.00073","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: Categorizing patients with cancer by their disease stage can be an important tool when conducting administrative claims-based studies. As claims databases frequently do not capture this information, algorithms are increasingly used to define disease stage. To our knowledge, to date, no study has used an algorithm to categorize patients with bladder cancer (BC) by disease stage (non-muscle-invasive BC [NMIBC], muscle-invasive BC [MIBC], or locally advanced/metastatic urothelial carcinoma [la/mUC]) in a US-based health care claims database.

Methods: A claims-based algorithm was developed to categorize patients by disease stage on the basis of the administrative claims portion of the SEER-Medicare linked data. The algorithm was validated against a reference SEER registry, and the algorithm's parameters were iteratively modified to improve its performance. Patients were included if they had an initial diagnosis of BC between January 2016 and December 2017 recorded in SEER registry data. Medicare claims data were available for these patients until December 31, 2019. The algorithm was evaluated by assessing percentage agreement, Cohen's kappa (κ), specificity, positive predictive value (PPV), and negative predictive value (NPV) against the SEER categorization.

Results: A total of 15,484 patients with SEER-confirmed BC were included: 10,991 (71.0%) with NMIBC, 3,645 (23.5%) with MIBC, and 848 (5.5%) with la/mUC. After multiple rounds of algorithm optimization, the final algorithm had an agreement of 82.5% with SEER, with a κ of 0.58, a PPV of 87.0% for NMIBC, and 76.8% for MIBC and a high NPV for la/mUC of 98.0%.

Conclusion: This claims-based algorithm could be a useful approach for researchers conducting claims-based studies categorizing patients with BC at diagnosis.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
利用 SEER-Medicare 索赔数据开发和优化膀胱癌算法。
目的:在进行以行政报销为基础的研究时,按疾病分期对癌症患者进行分类是一项重要工具。由于理赔数据库经常无法捕捉到这些信息,因此越来越多地使用算法来定义疾病分期。据我们所知,迄今为止,还没有一项研究在基于美国的医疗索赔数据库中使用算法按疾病分期(非肌浸润性膀胱癌[NMIBC]、肌浸润性膀胱癌[MIBC]或局部晚期/转移性尿路上皮癌[la/mUC])对膀胱癌(BC)患者进行分类:方法:根据 SEER-Medicare 链接数据中的行政索赔部分,开发了一种基于索赔的算法,按疾病分期对患者进行分类。该算法根据 SEER 登记参考数据进行了验证,并对算法参数进行了反复修改,以提高其性能。如果患者在 2016 年 1 月至 2017 年 12 月期间被初步诊断为 BC 并记录在 SEER 登记数据中,则将其纳入研究范围。这些患者的医疗保险理赔数据有效期至 2019 年 12 月 31 日。通过评估与 SEER 分类的一致性百分比、Cohen's kappa (κ)、特异性、阳性预测值 (PPV) 和阴性预测值 (NPV),对算法进行评估:共纳入 15,484 名 SEER 确诊的 BC 患者:其中10991例(71.0%)为NMIBC,3645例(23.5%)为MIBC,848例(5.5%)为la/mUC。经过多轮算法优化后,最终算法与 SEER 的一致性为 82.5%,κ 为 0.58,NMIBC 的 PPV 为 87.0%,MIBC 为 76.8%,la/mUC 的 NPV 高达 98.0%:这种基于索赔的算法对于研究人员在诊断时对 BC 患者进行分类的索赔研究来说是一种有用的方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
6.20
自引率
4.80%
发文量
190
期刊最新文献
Identifying Oncology Patients at High Risk for Potentially Preventable Emergency Department Visits Using a Novel Definition. Use of Patient-Reported Outcomes in Risk Prediction Model Development to Support Cancer Care Delivery: A Scoping Review. Optimizing End Points for Phase III Cancer Trials. Patients Facing Large Language Models in Oncology: A Narrative Review. Remote Patient Monitoring Using Mobile Health Technology in Cancer Care and Research: Patients' Views and Preferences.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1